Puriblood Medical Co., Ltd. (TPEX:6847)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
58.30
+8.60 (17.30%)
Apr 29, 2026, 1:36 PM CST
-27.31%
Market Cap 829.61M
Revenue (ttm) 117.35M
Net Income (ttm) -7.47M
Shares Out 14.23M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,618
Average Volume 34,183
Open 49.70
Previous Close 49.70
Day's Range 49.70 - 58.30
52-Week Range 47.75 - 90.70
Beta 0.06
RSI 51.53
Earnings Date Apr 30, 2026

About Puriblood Medical

Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan. The company offers leukoreduction, cell separation, and P-Tex, an advanced anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsinchu City, Taiwan. [Read more]

Sector Healthcare
Founded 2015
Employees 44
Stock Exchange Taipei Exchange
Ticker Symbol 6847
Full Company Profile

Financial Performance

In 2024, Puriblood Medical's revenue was 110.67 million, a decrease of -11.65% compared to the previous year's 125.27 million. Losses were -5.37 million, -89.60% less than in 2023.

Financial Statements

News

There is no news available yet.